{"id":8580,"date":"2021-12-17T01:48:27","date_gmt":"2021-12-17T06:48:27","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/nesiritide-bnp-32-humain-cas-124584-08-3-peptide-natriuretique-cerebral-pour-linsuffisance-cardiaque\/"},"modified":"2021-12-17T01:48:27","modified_gmt":"2021-12-17T06:48:27","slug":"nesiritide-bnp-32-humain-cas-124584-08-3-peptide-natriuretique-cerebral-pour-linsuffisance-cardiaque","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/fr\/product\/nesiritide-bnp-32-humain-cas-124584-08-3-peptide-natriuretique-cerebral-pour-linsuffisance-cardiaque\/","title":{"rendered":"Nesiritide \/ BNP-32 (HUMAIN) CAS 124584-08-3 Peptide natriur\u00e9tique c\u00e9r\u00e9bral pour l&#39;insuffisance cardiaque"},"content":{"rendered":"<h2><strong>Nesiritide \/ BNP-32 (HUMAIN) CAS 124584-08-3 Peptide natriur\u00e9tique c\u00e9r\u00e9bral pour l&#39;insuffisance cardiaque<\/strong><\/h2>\n<p>Nom du produit\u00a0: Nesiritide \/ BNP-32 (HUMAIN)<br \/>\nSynonymes\u00a0: Nesiritide,Brain Natriuretic Peptide-32 human,BNP-32, &gt;98\u00a0%\u00a0;BNP-32 (humain) chlorhydrate\u00a0;Nesiritide [USAN\u00a0: INN] ;SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH (PONT DISULFURE : 10-26);SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER -SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS;H-SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY -ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS-OH;H-SER-PRO-LYS -MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL -LEU-ARG-ARG-HIS-OH (PONT DISULFURE\u00a0: 10-26\u00a0); PEPTIDE NATRIURETIQUE DU CERVEAU (1-32), HUMAIN<br \/>\nCAS\u00a0: 124584-08-3<br \/>\nMF\u00a0: C143H244N50O42S4<br \/>\nMW\u00a0: 3464.04<br \/>\nEINECS : 1312995-182-4<br \/>\nCat\u00e9gories de produits :<br \/>\nMol File : 124584-08-3.mol<\/p>\n<p>Le n\u00e9siritide a \u00e9t\u00e9 introduit aux \u00c9tats-Unis en tant que nouveau traitement intraveineux pour les patients atteints de insuffisance cardiaque congestive d\u00e9compens\u00e9e aigu\u00eb qui ont une dyspn\u00e9e au repos ou avec une activit\u00e9 minimale it\u00e9. Le n\u00e9siritide est la premi\u00e8re forme humaine recombinante du puissant peptide natriur\u00e9tique de type B vasodilatateur (\u00e9galement connu sous le nom de peptide natriur\u00e9tique c\u00e9r\u00e9bral), un peptide naturel de 32 acides amin\u00e9s avec une structure cyclique de 17 acides amin\u00e9s \u00e0 pont disulfure. Le n\u00e9siritide se lie au r\u00e9cepteur peptidique natriur\u00e9tique de type A \u00e0 la surface des cellules endoth\u00e9liales et musculaires lisses, stimulant la production du second messager cGMP qui m\u00e9die principalement la relaxation des cellules musculaires lisses vasculaires. Il facilite \u00e9galement l&#39;\u00e9limination du sodium et de l&#39;eau par les reins et diminue la s\u00e9cr\u00e9tion de certaines hormones, telles que l&#39;adr\u00e9naline, l&#39;angiotensine II, l&#39;aldost\u00e9rone et l&#39;endoth\u00e9line, qui provoquent des effets n\u00e9fastes \u00e0 long terme, notamment la constriction des vaisseaux sanguins et l&#39;\u00e9l\u00e9vation de la pression art\u00e9rielle. Dans les essais cliniques men\u00e9s aupr\u00e8s de patients insuffisants cardiaques, le n\u00e9sidtide a r\u00e9duit de mani\u00e8re dose-d\u00e9pendante la pression capillaire pulmonaire, la pression auriculaire droite et la r\u00e9sistance vasculaire syst\u00e9mique et augment\u00e9 l&#39;index cardiaque sans affecter la fr\u00e9quence cardiaque. Le principal effet ind\u00e9sirable observ\u00e9 \u00e9tait une hypotension dose-d\u00e9pendante. Dans un essai comparatif de phase III, le n\u00e9siritide s&#39;est av\u00e9r\u00e9 sup\u00e9rieur \u00e0 l&#39;iv. la nitroglyc\u00e9rine dans ses effets h\u00e9modynamiques ainsi que plus facile \u00e0 administrer et mieux tol\u00e9r\u00e9. Le n\u00e9siritide est \u00e9limin\u00e9 par clivage prot\u00e9olytique par l&#39;endopeptidase neutre enzymatique NEP24.11 et par liaison au r\u00e9cepteur peptidique natriur\u00e9tique de type C, suivi d&#39;une endocytose et d&#39;une hydrolyse lysosomale intracellulaire. Comme sa demi-vie est courte (18\u00a0min), le n\u00e9siritide est administr\u00e9 en bolus de 21\u00a0\u03bcg\/kg suivi d&#39;une perfusion d&#39;entretien continue \u00e0 0,011\u00a0\u03bcg\/kg\/min g\u00e9n\u00e9ralement sur 24 \u00e0 48 heures.<\/p>\n<p> <strong>N\u00e9siritide \/ BNP-32 (HUMAIN) CAS 124584-08-3 Propri\u00e9t\u00e9s chimiques<\/strong><br \/>\nBNP-32 (HUMAIN) Propri\u00e9t\u00e9s chimiques<br \/>\ndensit\u00e9 1,52\u00b10,1 g\/cm3 (pr\u00e9vue)<br \/>\nRTECS EE1534000<br \/>\ntemp. \u221220\u00b0C<br \/>\nform powder<br \/>\nWater Solubilit\u00e9 Soluble in water at 1mg\/ml<br \/>\nCAS DataBase Reference 124584-08-3<\/p>\n<p> <strong>Function and Application of Nesiritide \/ BNP-32 (HUMAN) CAS 124584-08-3<\/strong><br \/>\nTraitement de l&#39;insuffisance cardiaque congestive (antagoniste du syst\u00e8me r\u00e9nine-angiotensine).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nom du produit\u00a0: Nesiritide \/ BNP-32 (HUMAIN)<br \/>\nCAS\u00a0: 124584-08-3<br \/>\nMF\u00a0: C143H244N50O42S4<br \/>\nMW\u00a0: 3464.04<br \/>\nEINECS\u00a0: 1312995-182-4<br \/>\nCat\u00e9gories de produits\u00a0: &lt; &amp;&gt;Fichier Mol\u00a0: 124584-08-3.mol<\/p>\n","protected":false},"featured_media":2290,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[497],"product_tag":[1140],"class_list":{"0":"post-8580","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptide-du-systeme-cardiovasculaire","7":"product_tag-nesiritide-bnp-32-human-cas-124584-08-3-brain-natriuretic-peptide-for-heart-failure-fr","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/product\/8580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/comments?post=8580"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/media?parent=8580"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/product_brand?post=8580"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/product_cat?post=8580"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/fr\/wp-json\/wp\/v2\/product_tag?post=8580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}